Anaemia is characterized by classic symptoms such as headaches, shortness of breath, and palpitations. The primary nutritional factors that can cause anaemia are deficiencies in B12, Folate, and Iron.

Pernicious anaemia is a condition that results in a deficiency of vitamin B12 due to an autoimmune disorder affecting the gastric mucosa. The term pernicious refers to the gradual and subtle harm caused by the condition, which often leads to delayed diagnosis. While pernicious anaemia is the most common cause of vitamin B12 deficiency, other causes include atrophic gastritis, gastrectomy, and malnutrition. The condition is characterized by the presence of antibodies to intrinsic factor and/or gastric parietal cells, which can lead to reduced vitamin B12 absorption and subsequent megaloblastic anaemia and neuropathy.

Pernicious anaemia is more common in middle to old age females and is associated with other autoimmune disorders such as thyroid disease, type 1 diabetes mellitus, Addison’s, rheumatoid, and vitiligo. Symptoms of the condition include anaemia, lethargy, pallor, dyspnoea, peripheral neuropathy, subacute combined degeneration of the spinal cord, neuropsychiatric features, mild jaundice, and glossitis. Diagnosis is made through a full blood count, vitamin B12 and folate levels, and the presence of antibodies.

Management of pernicious anaemia involves vitamin B12 replacement, usually given intramuscularly. Patients with neurological features may require more frequent doses. Folic acid supplementation may also be necessary. Complications of the condition include an increased risk of gastric cancer.

Understanding Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation in the rectum and spreads continuously without going beyond the ileocaecal valve. It is most commonly seen in people aged 15-25 years and 55-65 years. The symptoms of ulcerative colitis are insidious and intermittent, including bloody diarrhea, urgency, tenesmus, abdominal pain, and extra-intestinal features. Diagnosis is done through colonoscopy and biopsy, but in severe cases, a flexible sigmoidoscopy is preferred to avoid the risk of perforation. The typical findings include red, raw mucosa that bleeds easily, widespread ulceration with preservation of adjacent mucosa, and inflammatory cell infiltrate in lamina propria. Extra-intestinal features of inflammatory bowel disease include arthritis, erythema nodosum, episcleritis, osteoporosis, uveitis, pyoderma gangrenosum, clubbing, and primary sclerosing cholangitis. Ulcerative colitis is linked with sacroiliitis, and a barium enema can show the whole colon affected by an irregular mucosa with loss of normal haustral markings.

The second segment of the duodenum is situated behind the peritoneum and contains the major and minor duodenal papillae.

Based on the symptoms described, the woman is likely experiencing biliary colic, which is characterized by intermittent pain that worsens after consuming fatty meals. Blockages in the biliary tree, typically caused by stones, can occur at any point, but in this case, it is likely in the cystic duct, as there is no mention of jaundice and the stool is normal.

The cystic duct joins with the right and left hepatic ducts to form the common bile duct, which then merges with the pancreatic duct to create the common hepatopancreatic duct. The major papilla, located in the second segment of the duodenum, is where these ducts empty into the duodenum. This segment is also situated behind the peritoneum.

Peptic ulcers affecting the duodenum are most commonly found in the first segment.

The third segment of the duodenum can be compressed by the superior mesenteric artery, leading to superior mesenteric artery syndrome, particularly in individuals with low body fat.

The fourth segment of the duodenum runs close to the abdominal aorta and can be compressed by an abdominal aortic aneurysm.

The ligament of Treitz attaches the duodenojejunal flexure to the diaphragm and is not associated with any particular pathology.

The retroperitoneal structures are those that are located behind the peritoneum, which is the membrane that lines the abdominal cavity. These structures include the duodenum (2nd, 3rd, and 4th parts), ascending and descending colon, kidneys, ureters, aorta, and inferior vena cava. They are situated in the back of the abdominal cavity, close to the spine. In contrast, intraperitoneal structures are those that are located within the peritoneal cavity, such as the stomach, duodenum (1st part), jejunum, ileum, transverse colon, and sigmoid colon. It is important to note that the retroperitoneal structures are not well demonstrated in the diagram as the posterior aspect has been removed, but they are still significant in terms of their location and function.

The facial nerve is situated at the surface of the parotid gland, followed by the retromandibular vein at a slightly deeper level, and the arterial layer at the deepest level.

The parotid gland is located in front of and below the ear, overlying the mandibular ramus. Its salivary duct crosses the masseter muscle, pierces the buccinator muscle, and drains adjacent to the second upper molar tooth. The gland is traversed by several structures, including the facial nerve, external carotid artery, retromandibular vein, and auriculotemporal nerve. The gland is related to the masseter muscle, medial pterygoid muscle, superficial temporal and maxillary artery, facial nerve, stylomandibular ligament, posterior belly of the digastric muscle, sternocleidomastoid muscle, stylohyoid muscle, internal carotid artery, mastoid process, and styloid process. The gland is supplied by branches of the external carotid artery and drained by the retromandibular vein. Its lymphatic drainage is to the deep cervical nodes. The gland is innervated by the parasympathetic-secretomotor, sympathetic-superior cervical ganglion, and sensory-greater auricular nerve. Parasympathetic stimulation produces a water-rich, serous saliva, while sympathetic stimulation leads to the production of a low volume, enzyme-rich saliva.

Fistulas are often seen in patients with Crohn’s disease due to the erosion of the submucosal layer, which can lead to full-thickness ulcers. If these ulcers penetrate the bowel and reach the bladder, they can create a pathway for undigested food to enter the bladder.

While bloody stool is commonly associated with ulcerative colitis (UC), it can also occur in Crohn’s disease. However, this symptom alone cannot explain the patient’s urinary tract infections or the passing of tomato skin.

Crypt abscesses are not present in Crohn’s disease and are only associated with UC. Therefore, they cannot explain the patient’s symptoms.

Goblet cell loss, which refers to the loss of mucin-secreting cells in the intestine, is only seen in UC and not in Crohn’s disease.

Inflammatory bowel disease (IBD) is a condition that includes two main types: Crohn’s disease and ulcerative colitis. Although they share many similarities in terms of symptoms, diagnosis, and treatment, there are some key differences between the two. Crohn’s disease is characterized by non-bloody diarrhea, weight loss, upper gastrointestinal symptoms, mouth ulcers, perianal disease, and a palpable abdominal mass in the right iliac fossa. On the other hand, ulcerative colitis is characterized by bloody diarrhea, abdominal pain in the left lower quadrant, tenesmus, gallstones, and primary sclerosing cholangitis. Complications of Crohn’s disease include obstruction, fistula, and colorectal cancer, while ulcerative colitis has a higher risk of colorectal cancer than Crohn’s disease. Pathologically, Crohn’s disease lesions can be seen anywhere from the mouth to anus, while ulcerative colitis inflammation always starts at the rectum and never spreads beyond the ileocaecal valve. Endoscopy and radiology can help diagnose and differentiate between the two types of IBD.

Femoral hernias are more common in women, with female gender and pregnancy being identified as risk factors. A femoral hernia occurs when abdominal viscera or omentum protrudes through the femoral ring and into the femoral canal, with the neck of the hernia located below and lateral to the pubic tubercle. Although males can also develop femoral hernias, the condition is more prevalent in females with a ratio of 3:1.

Understanding Femoral Hernias

Femoral hernias occur when a part of the bowel or other abdominal organs pass through the femoral canal, which is a potential space in the anterior thigh. This can result in a lump in the groin area that is mildly painful and typically non-reducible. It is important to differentiate femoral hernias from inguinal hernias, which are located in a different area. Femoral hernias are less common than inguinal hernias and are more prevalent in women, especially those who have had multiple pregnancies.

Diagnosis of femoral hernias is usually clinical, but ultrasound can also be used. It is important to rule out other possible causes of a lump in the groin area, such as lymphadenopathy, abscess, or aneurysm. Complications of femoral hernias include incarceration, strangulation, bowel obstruction, and bowel ischaemia, which can lead to significant morbidity and mortality.

Surgical repair is necessary for femoral hernias, as the risk of strangulation is high. This can be done laparoscopically or via a laparotomy. Hernia support belts or trusses should not be used for femoral hernias due to the risk of strangulation. In emergency situations, a laparotomy may be the only option. Understanding the features, epidemiology, diagnosis, complications, and management of femoral hernias is crucial for healthcare professionals to provide appropriate care for their patients.

Pseudo-Obstruction and its Causes

Pseudo-obstruction is a condition that can be caused by various factors, including hypothyroidism, hypokalaemia, diabetes, uraemia, and hypocalcaemia. In the case of hypothyroidism, the slowness and hypothermia of the patient suggest that this may be the underlying cause of the pseudo-obstruction. However, other factors should also be considered.

It is important to note that pseudo-obstruction is a condition that affects the digestive system, specifically the intestines. It is characterized by symptoms that mimic those of a bowel obstruction, such as abdominal pain, bloating, and constipation. However, unlike a true bowel obstruction, there is no physical blockage in the intestines.

To diagnose pseudo-obstruction, doctors may perform various tests, including X-rays, CT scans, and blood tests. Treatment options may include medications to stimulate the intestines, changes in diet, and surgery in severe cases.

Overall, it is important to identify the underlying cause of pseudo-obstruction in order to provide appropriate treatment and management of the condition.

The most significant risk factor for developing oesophageal adenocarcinoma, one of the two types of oesophageal carcinomas in the UK, is Barrett’s oesophagus. This condition occurs when chronic acid exposure causes a metaplastic change from squamous epithelium to gastric columnar epithelium in the lower end of the oesophagus, increasing the risk of developing adenocarcinoma.

Duodenal adenocarcinoma, a relatively rare cancer of the gastrointestinal tract, is often caused by genetic conditions such as HNCCP/Lynch syndrome and familial adenomatous polyposis (FAP), as well as Crohn’s disease. Patients with this type of cancer typically experience abdominal pain, reflux, and weight loss due to the malignancy obstructing the flow of digested chyme from the stomach to the jejunum.

Gastric malignancy, the most common type of which is adenocarcinoma, is not associated with Barrett’s oesophagus. Symptoms of gastric cancer include heartburn, abdominal pain, loss of appetite, and early satiety, and the most significant risk factor is H. pylori infection.

Oesophageal leiomyoma, a benign tumour, is not linked to Barrett’s oesophagus. Patients may experience reflux if the mass enlarges, but the most common symptoms are retrosternal discomfort and difficulty swallowing.

Squamous cell carcinoma, the other type of oesophageal malignancy, is associated with smoking and alcohol and tends to occur in the upper oesophagus. Unlike adenocarcinoma, weight loss is usually an early symptom of this type of cancer.

Barrett’s oesophagus is a condition where the lower oesophageal mucosa is replaced by columnar epithelium, which increases the risk of oesophageal adenocarcinoma by 50-100 fold. It is usually identified during an endoscopy for upper gastrointestinal symptoms such as dyspepsia, as there are no screening programs for it. The length of the affected segment determines the chances of identifying metaplasia, with short (<3 cm) and long (>3 cm) subtypes. The prevalence of Barrett’s oesophagus is estimated to be around 1 in 20, and it is identified in up to 12% of those undergoing endoscopy for reflux.

The columnar epithelium in Barrett’s oesophagus may resemble that of the cardiac region of the stomach or that of the small intestine, with goblet cells and brush border. The single strongest risk factor for Barrett’s oesophagus is gastro-oesophageal reflux disease (GORD), followed by male gender, smoking, and central obesity. Alcohol is not an independent risk factor for Barrett’s, but it is associated with both GORD and oesophageal cancer. Patients with Barrett’s oesophagus often have coexistent GORD symptoms.

The management of Barrett’s oesophagus involves high-dose proton pump inhibitor, although the evidence base for its effectiveness in reducing the progression to dysplasia or inducing regression of the lesion is limited. Endoscopic surveillance with biopsies is recommended every 3-5 years for patients with metaplasia but not dysplasia. If dysplasia of any grade is identified, endoscopic intervention is offered, such as radiofrequency ablation, which is the preferred first-line treatment, particularly for low-grade dysplasia, or endoscopic mucosal resection.

Large bowel obstruction is the most likely diagnosis based on the pattern of symptoms, which include abdominal distension, absence of passing flatus or stool, and late onset or no vomiting.

Large bowel obstruction occurs when there is a blockage in the passage of food, fluids, and gas through the large intestines. The most common cause of this condition is a tumor, accounting for 60% of cases. Colonic malignancy is often the initial presenting complaint in approximately 30% of cases, especially in more distal colonic and rectal tumors due to their smaller lumen diameter. Other causes include volvulus and diverticular disease.

Clinical features of large bowel obstruction include abdominal pain, distention, and absence of passing flatus or stool. Nausea and vomiting may suggest a more proximal lesion, while peritonism may be present if there is associated bowel perforation. It is important to consider the underlying causes, such as recent symptoms suggestive of colorectal cancer.

Abdominal x-ray is still commonly used as a first-line investigation, with a diameter greater than the normal limits of 10-12 cm for the caecum, 8 cm for the ascending colon, and 6.5 cm for recto-sigmoid being diagnostic of obstruction. CT scan is highly sensitive and specific for identifying obstruction and its underlying cause.

Initial management of large bowel obstruction includes NBM, IV fluids, and nasogastric tube with free drainage. Conservative management for up to 72 hours can be trialed if the cause of obstruction does not require surgery, after which further management may be required if there is no resolution. Around 75% of cases will eventually require surgery. IV antibiotics are given if perforation is suspected or surgery is planned. Emergency surgery is necessary if there is any overt peritonitis or evidence of bowel perforation, involving irrigation of the abdominal cavity, resection of perforated segment and ischaemic bowel, and addressing the underlying cause of the obstruction.

Ranitidine competes with histamine for binding to H2 receptors on gastric parietal cells, acting as an antagonist. It is not associated with sexual disinhibition, but can cause sexual dysfunction such as decreased libido and impotence. When the stomach pH drops too low, somatostatin secretion is stimulated, which inhibits acid secretion by parietal cells and also suppresses the release of positive regulators like histamine and gastrin. Ranitidine enhances the function of somatostatin rather than inhibiting it. As a result, it suppresses both normal and meal-stimulated acid secretion by parietal cells, making the third and fourth options incorrect.

Histamine-2 Receptor Antagonists and their Withdrawal from the Market

Histamine-2 (H2) receptor antagonists are medications used to treat dyspepsia, which includes conditions such as gastritis and gastro-oesophageal reflux disease. They were previously considered a first-line treatment option, but have since been replaced by more effective proton pump inhibitors. One example of an H2 receptor antagonist is ranitidine.

However, in 2020, ranitidine was withdrawn from the market due to the discovery of small amounts of the carcinogen N-nitrosodimethylamine (NDMA) in products from multiple manufacturers. This led to concerns about the safety of the medication and its potential to cause cancer. As a result, patients who were taking ranitidine were advised to speak with their healthcare provider about alternative treatment options.